Insuman Comb 25

Insulin human, the active ingredient in Insuman Comb 25, is a insulin presented as a subcutaneous injectable for diabetes management. It is used to lower blood glucose in patients with type 1 and type 2 diabetes mellitus.\n\nGNH India supplies Insuman Comb 25 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Insuman Comb 25 is an insulin preparation indicated for the treatment of diabetes mellitus.\n\n- Type 1 diabetes mellitus: provides basal and prandial insulin coverage to achieve target glycaemic control.\n- Type 2 diabetes mellitus: improves glycaemic control when oral agents are insufficient or when insulin therapy is required.

Common Side Effects:\n- Hypoglycaemia: low blood glucose episodes, especially if meals are missed or dose is excessive.\n- Injection‑site reactions: redness, swelling, or itching at the injection site.\n- Weight gain: increased caloric storage associated with improved glucose utilisation.\n- Lipodystrophy: localized thickening or atrophy of subcutaneous fat with repeated injections.\n- Edema: mild fluid retention, particularly in the lower extremities.\n- Localised allergic reactions: mild rash or urticaria at the site.\n\nSerious or Rare Side Effects:\n- Severe hypoglycaemia: prolonged loss of consciousness or seizures requiring emergency care.\n- Anaphylactic reaction: systemic allergic response that can be life‑threatening.\n- Insulin antibody formation: may alter insulin effectiveness and cause unpredictable glucose control.\n- Hypokalemia: low serum potassium secondary to rapid glucose shift into cells.

Patients receiving Insuman Comb 25 should be monitored closely for glycaemic trends and dose adjustments.\n\n- Monitor blood glucose regularly: adjust dose based on fasting and post‑prandial readings.\n- Adjust dose during illness or stress: hyperglycaemia may require temporary dose increase.\n- Avoid use in patients with hypoglycaemia unawareness without proper education.\n- Use caution in renal or hepatic impairment: insulin clearance may be reduced.\n- Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insuman Comb 25 may interact with several drug classes that affect glucose homeostasis.\n\nMajor Interactions (Avoid):\n- Sulfonylureas: additive risk of severe hypoglycaemia.\n- Beta‑blockers: can mask hypoglycaemia symptoms.\n- MAO inhibitors: may potentiate insulin’s glucose‑lowering effect.\n\nModerate Interactions (Monitor Closely):\n- ACE inhibitors: may enhance insulin sensitivity, requiring dose review.\n- Thiazide diuretics: can increase blood glucose, necessitating closer monitoring.\n- Oral contraceptives: may alter glucose control, prompting dose adjustments.